Allergan has repeatedly rejected Valeant's offers to buy the company, the latest for about $53 billion in cash and stock, saying Valeant is substantially undervaluing the company and that an independent Allergan can generate more value for shareholders.» Read More
Pfizer CEO Ian Read recently met with U.K.-based investors to discuss a second bid for AstraZeneca, valuing the firm at $106 billion, sources said.
May 1- Pfizer Inc may sweeten its offer for Britain's AstraZeneca Plc to more than 63 billion pounds, or $106 billion, and raise the cash portion of the deal, to kickstart negotiations, Bloomberg reported on Thursday.
PARIS, April 30- General Electric's overtures to the power business of France's former industrial beacon Alstom have shown again how the French state, for all its interventionist zeal, has limited room for manoeuvre against big business.
Alstom has until June 2 to review General Electric's $13.5 billion bid for its energy assets, reports CNBC's Mary Thompson.
Alstom is accepting GE's $13.5 billion bid for its energy assets, reports CNBC's Mary Thompson.
Jeffrey Immelt, General Electric chairman & CEO, discusses how the synergies between GE and Alstrom will likely drive earnings and increase the company's industrial mix.
CNBC's Mary Thompson reports the latest details on General Electric's attempt to acquire French company Alstom.
Nicholas Heymann, William Blair analyst, discusses General Electric's attempt to acquire Alstrom but Germany's Siemens AG is not giving up its pursuit either. Currently GE has the green light from Alstrom shareholders, says Heymann.
LONDON, April 30- British oil company Heritage Oil agreed a 924 million pound takeover offer from a fund owned by the former chief executive of Qatar's sovereign wealth fund. Its suitor, Al Mirqab Capital, is the private investment vehicle of Qatar's Sheikh Hamad Bin Jassim Bin Jabor Al Thani and his family.
*Talks not exclusive, Alstom can hold talks with Siemens. The French transport-to-turbines group is also set to receive an offer from its much larger German competitor Siemens AG, which said it had sent a letter to Alstom after its managing and supervisory boards had decided to make an offer.
CNBC's David Faber reports Siemens will make an offer for Alstonm.
*Says planned public offer in UK unit to take place in "mid-term". MADRID, April 29- Spanish bank Santander launched a buyout offer for the remaining 25 percent of its Brazilian unit, cementing its grip on one of its top profit drivers in a deal worth up to 4.7 billion euros.
*Pfizer works on next move in takeover bid for Astrazeneca. Leading the Nasdaq down was Amazon.com, which extended Friday's sharp drop a day after its earnings report. Shares of Pfizer gained 4.2 percent to $32.04 after the U.S. drugmaker was said to be working on its next move in a potential bid to take over Britain's AstraZeneca Plc.
*Pfizer works on next move in takeover bid for Astrazeneca. Leading the Nasdaq down was Amazon.com, which extended Friday's sharp decline a day after its earnings report.
Jared Bernstein, senior fellow at The Center on Budget and Policy Priorities, and Rep. Todd Young, R-Ind., discusses how America's broken corporate tax code can cause companies, like Pfizer, to incorporate outside the U.S.
NEW YORK, April 28- Shares of AstraZeneca surged on Monday after a takeover offer, lifting global equity markets on speculation of further corporate deal-making, while crude oil prices fell on increased U.S. sanctions against Russia over the Ukraine crisis.
Discussing Pfizer's push for a $100 billion deal for AstraZeneca, with Seamus Fernandez Leerink Partners managing director.
Pfizer is working on its next move in a potential $100 billion battle for AstraZeneca after having two bids rejected. CNBC's Meg Tirrell reports buying AstraZeneca would boost Pfizer's cancer drug pipeline.
STOCKHOLM, April 28- Swedish drugmaker Meda rejected an improved takeover offer from U.S. generics firm Mylan which one person familiar with the matter said valued Meda at around $9 billion including debt, driving its shares sharply back down.
The "Squawk on the Street" team weigh in on Pfizer's bid to takeover European drug maker AstraZeneca.